



**NOVARTIS MASTER**  
**CLINICAL TRIAL AGREEMENT**  
**AMENDMENT**

Enclosed please find one fully executed original Master Clinical Trial Agreement Amendment.

Novartis Pharmaceuticals Corp  
One Health Plaza  
East Hanover, New Jersey 07936  
Trial Operations & Logistics  
US CD



**NOVARTIS PHARMACEUTICALS CORPORATION**  
**East Hanover, NJ 07936**

**MASTER CLINICAL TRIAL AGREEMENT (MCTA) – AMENDMENT #2**

The following is Amendment # 2 to the Master Clinical Trial Agreement (“Master Clinical Trial Agreement”), dated May 1, 2009, among The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas M.D. Anderson Cancer Center, The University of Texas Southwestern Medical Center, The University of Texas Medical Branch at Galveston, The University of Texas at Austin and The University of Texas Health Science Center at Tyler, each a member institution of The University of Texas System located at 201 West 7th Street, Austin, Texas 78701 (each an “Institution”) and Novartis Pharmaceuticals Corporation, a corporation with its principal office and place of business at 59 Route 10, East Hanover, NJ 07936 (“Novartis”). The place of business for the participating Institution in a Clinical Trial shall be outlined in the respective Attachment A, Clinical Trial Request Form (“CTRF”).

**RECITALS**

- A. Novartis and Institution wish to amend the terms of the Master Clinical Trial Agreement as set forth below to extend the term of this master agreement to April 30, 2019.

**Now Therefore**, it is hereby agreed as follows:

1. Section 2 of the Master Clinical Trial Agreement is hereby amended to include the following sentence at the end of the Section:

“The parties hereby agree to extend the Agreement Period from April 30, 2014 to April 30, 2019.”

2. The footer on this Master Clinical Trial Agreement shall be stricken and replaced with “Effective Date May 1, 2009 through April 30, 2014 – 5 year extension from April 30, 2014 through April 30, 2019. “

3. A new Section 6(D) is hereby added to the Master Clinical Trial Agreement and shall hereafter be and read as follows:

“The Institution and the Principal Investigator shall notify Novartis of each Serious Adverse Event encountered in the Clinical Trial within twenty-four (24) hours of becoming aware of it in accordance with the instructions set forth in the Protocol. Each such notice shall be given by telefax, whether or not notification was initially given by telephone and, if possible, on a Novartis Serious Adverse Event Report form as provided by Novartis. Paragraph D of this Section shall apply to both the original copy of each Serious Adverse Event Report form and the telefax confirmation sheet reflecting its transmission to Novartis.”

4. All other terms and conditions set forth in the Master Clinical Trial Agreement remain unchanged.

IN WITNESS WHEREOF, the parties have executed this Amendment #2 to the Master Clinical Trial Agreement in duplicate by proper persons thereunto duly authorized.

**NOVARTIS PHARMACEUTICALS CORPORATION**

By: [Signature]  
Name: \_\_\_\_\_  
(print or type)

Title: \_\_\_\_\_

Date: 4/10/14

**THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER**

By: [Signature]  
Name: **David Anderson**  
Director, Pre-Award Services

Title: \_\_\_\_\_

Date: 3/20/14

**THE UNIVERSITY OF TEXAS AT AUSTIN**

By: [Signature]  
Name: **Bill Catlett**  
~~Director~~  
Office of Industry Engagement

Title: \_\_\_\_\_

Date: 03 APR 14

**THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON**

By: [Signature]  
Name: **Karen S. Niemeler**  
Director, Contracts

Title: **Office of Sponsored Projects**

Date: 3/21/2014

**THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON**

By: [Signature]  
Name: **Connie J Barton**  
(print or type)

Title: **Director, OSP**

Date: 4/3/14

**THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO**

By: [Signature]  
Name: **Jane A. Youngers**  
(print or type)

Title: **Asst. Vice Pres. for Research Admin.**

Date: 4-4-14

**THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER**

By: [Signature]  
Name: **Angela R. Charboneau Wishon, J.D.**  
(print or type)  
Vice President for  
Research Administration

Date: 3-18-2014

**THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER**

By: [Signature]  
Name: \_\_\_\_\_  
(print or type)  
**Jaime Farias, MBA**

Title: **Assistant Director, Sponsored Program**

Date: 4/1/14

Reviewed and Approved by  
UTMDACC Legal Services for  
UTMDACC Signature:  
[Signature] #38812  
/CS2013-00037464-02